A newly identified 45‐kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance

Lignende værker

• Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms
  af: Sivahari P. Gorantla, et al.
  Udgivet: (2024-07-01)
• THE JAK2V617F POINT MUTATION INCREASES THE OSTEOCLAST FORMING ABILITY OF MONOCYTES IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS AND MAKES THEIR OSTEOCLASTS MORE SUSCEPTIBLE TO JAK2 INHIBITION
  af: Emmanouil Spanoudakis, et al.
  Udgivet: (2018-10-01)
• Association of JAK2 Haplotype GGCC_46/1 with the Response to Onco-Drug in MPNs Patients Positive for JAK2V617F Mutation
  af: Michela Perrone, et al.
  Udgivet: (2024-09-01)
• JAK2V617F Mutation in Endothelial Cells of Patients with Atherosclerotic Carotid Disease
  af: Reyhan Diz Küçükkaya, et al.
  Udgivet: (2024-09-01)
• Laboratory-developed Droplet Digital PCR Assay for Quantification of the JAK2^V617F Mutation
  af: Yupeng Liu, et al.
  Udgivet: (2024-06-01)